NCT07785154Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
Summary
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Inclusion criteria
• Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56). • Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment.
Exclusion criteria
• Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported. • Participating in an interventional clinical trial at the time of ICF signature. • Known allergic reactions to components of tagraxofusp. Note: Other protocol-specified criteria apply.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, Germany, Italy, Austria
- Sponsor
- Stemline Therapeutics, Inc.(Industry)
- Protocol no.
- STML-401-0521
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions
- Drug
Treatments studied
- Tagraxofusp
Locations · 41
- Bern, SwitzerlandInsel Gruppe AG, Bern University HospitalRecruiting at this site
- Lucerne, SwitzerlandLuzerner KantonsspitalRecruiting at this site
- Augsburg, GermanyUniversitätsklinikum AugsburgRecruiting at this site
- Bielefeld, GermanyHospital BielefeldRecruiting at this site
- Chemnitz, GermanyKlinikum ChemnitzRecruiting at this site
- Frankfurt, GermanyUniversity Clinic of FrankfurtRecruiting at this site
- Freiburg im Breisgau, GermanyUniversity clinic of FreiburgRecruiting at this site
- Halle, GermanyUniversitätsmedizin HalleRecruiting at this site
- Hamburg, GermanyAsklepios HamburgRecruiting at this site
- Hamburg, GermanyUniversity Medical Center Hamburg - EppendorfRecruiting at this site
- Kiel, GermanyCommunity Hospital KielRecruiting at this site
- Leipzig, GermanyUniversitätsklinikum Leipzig Klinik und Poliklinik für Hämatologie, Zelltherapie und HämostaseologieRecruiting at this site
- Lübeck, GermanyUniversitätsklinikum Schleswig-HolsteinRecruiting at this site
- Munich, GermanyTechnical University of MunichRecruiting at this site
- Oldenburg, GermanyOldenburghRecruiting at this site
- Tübingen, GermanyMedizinische Klinik Universitat TübingenRecruiting at this site
- Alessandria, ItalyAON SS Antonio e Biagio e C Arrigo Alessandria SOC EmatologiaRecruiting at this site
- Bologna, ItalyAOU di Bologna - Policlinico S. Orsola-Malpighi - UOC EmatologiaRecruiting at this site
- Catania, ItalyCTC U.O di Ematologia con Trapianto di Midollo Osseo - CataniaRecruiting at this site
- Cuneo, ItalyASO S. Croce e Carle - Cuneo - SC EmatologiaRecruiting at this site
- Ferrara, ItalyAOU Arcispedale Sant'Anna Cona (FE) - UOC Ematologia e Fisiopatologia della CoagulazioneRecruiting at this site
- Florence, ItalyAOU Careggi - Firenze - SOD EmatologiaRecruiting at this site
- Genova, ItalyIRCCS AOU San Martino - Genova - UO Clinica EmatologicaRecruiting at this site
- Genova, ItalyUO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino - GenoaRecruiting at this site
- Milan, ItalyFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milano - EmatologiaRecruiting at this site
- Milan, ItalySC Ematologia - ASST Grande Ospedale Metropolitano NiguardaRecruiting at this site
- Naples, ItalyAOU Federico II - UOC Ematologia e Trapianti di MidolloRecruiting at this site
- Padova, ItalyAOU di Padova - UO EmatologiaRecruiting at this site
- Palermo, ItalyAO Ospedali Riuniti Villa Sofia Cervello Palermo - UO Ematologia con UTMORecruiting at this site
- Pavia, ItalyFondazione IRCCS Policlinico San Matteo Pavia UO EmatologiaRecruiting at this site
In total, worldwide, all 41 sites listed in the registry are recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: August 25, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
+ 11 more locations
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.